Cure My Disease

Don't miss your cure!

 Log in / Sign up

AI takes on cancer radiotherapy: can a computer plan treatment in minutes?

NCT ID NCT05653063

Knowledge-focused Sponsor: University College, London Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jul 22, 2026 · Last updated Jul 23, 2026 · Updated 1 time

Summary

This trial tests whether an artificial intelligence program can automate two key steps in radiotherapy planning: outlining areas at risk of tumor spread or radiation damage, and designing the radiation beams. The AI tool is compared against the standard manual process done by oncologists and physicists. Over 1,000 patients with prostate, head and neck, or cervical cancer will participate to see if AI-generated plans meet clinical quality standards.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
a web-based artificial intelligence auto-planning tool that automates contouring and beam design for radiotherapy
What this could lead to
If successful, AI could speed up radiotherapy planning from weeks to minutes, reduce human workload, and improve treatment accuracy for thousands of cancer patients.
What could go wrong
The AI plans must meet strict clinical standards; early-stage technology may fail in complex cases or require human oversight, limiting real-world use.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

1,029 people

The number who actually took part.

Started

Dec 2023

Expected to finish

Sep 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Patients eligible for radiotherapy for head and neck, cervical or prostate cancer.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Consecutive patients with histologically confirmed head and neck cancers of the oropharynx, larynx, hypopharynx and nasopharynx (Stage I-III) that have given consent for radical radiotherapy. 2. Consecutive histologically confirmed primary cervical cancer patients (Stage IB-IIIB including pelvic node positive) that have given consent for radical radiotherapy. 3. Consecutive histologically confirmed primary prostate cancer patients (T1-4N0M0) that have given consent for radical radiotherapy. 4. Mental capacity to understand and consent to participate in the study. 5. Patients aged ≥18years. Exclusion Criteria: 1. Patients requiring radiotherapy after curative surgery or surgery that is intended to remove as much of the tumour as possible. 2. Patients receiving palliative radiotherapy 3. Patients aged \< 18years.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Cancer cervix are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cervical cancer cervical carcinoma head and neck cancer Head and Neck Neoplasms prostate cancer prostate carcinoma Uterine Cervical Neoplasms

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Cancer cervix Cancer head neck Cancer of prostate

Contacts and locations

Locations

  • Groote Schuur Hospital

    Cape Town, South Africa

  • King Hussein Cancer Center

    Amman, Jordan

  • Tata Medical Centre

    Kolkata, India

  • Tata Memorial Hospital

    Mumbai, India

  • Tygerberg Hospital

    Stellenbosch, South Africa

  • University of Malaya Medical Center

    Kuala Lumpur, Malaysia

More trials for these conditions

Other studies related to the condition(s) this trial covers.